ADAM and ADAMTS family proteins and snake venom metalloproteinases: A structural overview

Toxins

Volumn 8, Issue 5, 2016, Pages

  Takeda, Soichi ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

ADAM; Adamalysin; ADAMTS; Crystal structure; Disintegrin; MDC; Metalloproteinase; Reprolysin; Shedding; Snake venom

Indexed keywords

ADAM PROTEIN; ADAMTS PROTEIN; M12B PROTEINASE; MATRIX METALLOPROTEINASE; METALLOPROTEINASE; PROTEINASE; SNAKE VENOM; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; VON WILLEBRAND FACTOR;

AMINO ACID SEQUENCE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; OSTEOARTHRITIS; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; ANIMAL; CHEMISTRY; ENZYMOLOGY; HUMAN; METABOLISM; PROTEIN CONFORMATION;

ADAM PROTEINS; ANIMALS; HUMANS; METALLOENDOPEPTIDASES; PROTEIN CONFORMATION; SNAKE VENOMS; VON WILLEBRAND FACTOR;

EID: 84969135857     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins8050155     Document Type: Review

References (171)

1. Edwards, D.R.; Handsley, M.M.; Pennington, C.J. The ADAM metalloproteinases. Mol. Asp. Med. 2009, 29, 258-289. [CrossRef] [PubMed]
2. Reiss, K.; Saftig, P. The "A Disintegrin and Metalloprotease" (ADAM) family of sheddases: Physiological and cellular functions. Semin. Cell Dev. Biol. 2009, 20, 126-137. [CrossRef] [PubMed]
3. Weber, S.; Saftig, P. Ectodomain shedding and ADAMs in development. Development 2012, 139, 3693-3709. [CrossRef] [PubMed]
4. Black, R.A.; Rauch, C.T.; Kozlosky, C.J.; Peschon, J.J.; Slack, J.L.;Wolfson, M.F.; Castner, B.J.; Stocking, K.L.; Reddy, P.; Srinivasan, S.; et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997, 385, 729-733. [CrossRef] [PubMed]
5. Moss, M.L.; Jin, S.L.; Milla, M.E.; Bickett, D.M.; Burkhart, W.; Carter, H.L.; Chen, W.J.; Clay, W.C.; Didsbury, J.R.; Hassler, D.; et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997, 385, 733-736. [CrossRef] [PubMed]
6. Blaydon, D.C.; Biancheri, P.; Di,W.L.; Plagnol, V.; Cabral, R.M.; Brooke, M.A.; van Heel, D.A.; Ruschendorf, F.; Toynbee,M.;Walne, A.; et al. Inflammatory skin and bowel disease linked to ADAM17 deletion. N. Engl. J. Med. 2011, 365, 1502-1508. [CrossRef] [PubMed]
7. Atapattu, L.; Lackmann,M.; Janes, P.W. The role of proteases in regulating Eph/ephrin signaling. Cell Adh. Migr. 2014, 8, 294-307. [CrossRef] [PubMed]
8. Murphy, G. The ADAMs: Signalling scissors in the tumour microenvironment. Nat. Rev. Cancer 2008, 8, 929-941. [CrossRef] [PubMed]
9. Mochizuki, S.; Okada, Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 2007, 98, 621-628. [CrossRef] [PubMed]
10. Zhang, P.; Shen, M.; Fernandez-Patron, C.; Kassiri, Z. ADAMs family and relatives in cardiovascular physiology and pathology. J. Mol. Cell Cardiol. 2015, 93, 186-199. [CrossRef] [PubMed]
11. Van Eerdewegh, P.; Little, R.D.; Dupuis, J.; Del Mastro, R.G.; Falls, K.; Simon, J.; Torrey, D.; Pandit, S.; McKenny, J.; Braunschweiger, K.; et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 2002, 418, 426-430. [CrossRef] [PubMed]
12. Blobel, C.P.; Wolfsberg, T.G.; Turck, C.W.; Myles, D.G.; Primakoff, P.; White, J.M. A potential fusion peptide and an integrin ligand domain in a protein active in sperm-egg fusion. Nature 1992, 356, 248-252. [CrossRef] [PubMed]
13. Fukata, Y.; Adesnik, H.; Iwanaga, T.; Bredt, D.S.; Nicoll, R.A.; Fukata, M. Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate synaptic transmission. Science 2006, 313, 1792-1795. [CrossRef] [PubMed]
14. Kelwick, R.; Desanlis, I.; Wheeler, G.N.; Edwards, D.R. The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family. Genome Biol. 2015, 16, 113. [CrossRef] [PubMed]
15. Apte, S.S. A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (ADAMTS) superfamily-functions andmechanisms. J. Biol. Chem. 2009, 284, 31493-31497. [CrossRef] [PubMed]
16. Dubail, J.; Apte, S.S. Insights on ADAMTS proteases and ADAMTS-like proteins from mammalian genetics. Matrix Biol. 2015, 44-46, 24-37. [CrossRef] [PubMed]
17. Levy, G.G.; Nichols, W.C.; Lian, E.C.; Foroud, T.; McClintick, J.N.; McGee, B.M.; Yang, A.Y.; Siemieniak, D.R.; Stark, K.R.; Gruppo, R.; et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001, 413, 488-494. [CrossRef] [PubMed]
18. Sadler, J.E.; Moake, J.L.; Miyata, T.; George, J.N. Recent advances in thrombotic thrombocytopenic purpura. Hematol. Am. Soc. Hematol. Educ. Progr. 2004, 2004, 407-423. [CrossRef] [PubMed]
19. Tsai, H.M.; Lian, E.C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N. Engl. J. Med. 1998, 339, 1585-1594. [CrossRef] [PubMed]
20. Troeberg, L.; Nagase, H. Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim. Biophys. Acta 2012, 1824, 133-145. [CrossRef] [PubMed]
21. Gao, W.; Zhu, J.; Westfield, L.A.; Tuley, E.A.; Anderson, P.J.; Sadler, J.E. Rearranging exosites in noncatalytic domains can redirect the substrate specificity of ADAMTS proteases. J. Biol. Chem. 2012, 287, 26944-26952. [CrossRef] [PubMed]
22. Zheng, X.L. ADAMTS13 and vonWillebrand Factor in Thrombotic Thrombocytopenic Purpura. Annu. Rev. Med. 2015, 66, 211-225. [CrossRef] [PubMed]
23. Kang, T.S.; Georgieva, D.; Genov, N.; Murakami, M.T.; Sinha, M.; Kumar, R.P.; Kaur, P.; Kumar, S.; Dey, S.; Sharma, S.; et al. Enzymatic toxins from snake venom: Structural characterization and mechanism of catalysis. FEBS J. 2011, 278, 4544-4576. [CrossRef] [PubMed]
24. McCleary, R.J.R.; Kini, R.M. Non-enzymatic proteins from snake venoms: A gold mine of pharmacological tools and drug leads. Toxicon 2013, 62, 56-74. [CrossRef] [PubMed]
25. Ivanov, C.P.; Ivanov, O.C. The evolution and ancestors of toxic proteins. Toxicon 1979, 17, 205-220. [CrossRef]
26. Fry, B.G.; Vidal, N.; Norman, J.A.; Vonk, F.J.; Scheib, H.; Ramjan, S.F.R.; Kuruppu, S.; Fung, K.; Hedges, S.B.; Richardson, M.K.; et al. Early evolution of the venom system in lizards and snakes. Nature 2006, 439, 584-588. [CrossRef] [PubMed]
27. Casewell, N.R. On the ancestral recruitment of metalloproteinases into the venom of snakes. Toxicon 2012, 60, 449-454. [CrossRef] [PubMed]
28. Takeda, S.; Igarashi, T.; Mori, H.; Araki, S. Crystal structures of VAP1 reveal ADAMs’ MDC domain architecture and its unique C-shaped scaffold. EMBO J. 2006, 25, 2388-2396. [CrossRef] [PubMed]
29. Calvete, J.J.; Juarez, P.; Sanz, L. Snake venomics. Strategy and applications. J. Mass Spectrom. 2007, 42, 1405-1414. [CrossRef] [PubMed]
30. Fox, J.W.; Serrano, S.M. Exploring snake venom proteomes: Multifaceted analyses for complex toxin mixtures. Proteomics 2008, 8, 909-920. [CrossRef] [PubMed]
31. Gutierrez, J.M.; Rucavado, A.; Gutiérrez, J.M.; Rucavado, A. Snake venom metalloproteinases: Their role in the pathogenesis of local tissue damage. Biochimie 2000, 82, 841-850. [CrossRef]
32. Moura-da-Silva, A.M.; Butera, D.; Tanjoni, I. Importance of snake venom metalloproteinases in cell biology:Effects on platelets, inflammatory and endothelial cells. Curr. Pharm. Des. 2007, 13, 2893-2905. [CrossRef] [PubMed]
33. Fox, J.W.; Serrano, S.M. Structural considerations of the snake venom metalloproteinases, key members of the M12 reprolysin family of metalloproteinases. Toxicon 2005, 45, 969-985. [CrossRef] [PubMed]
34. Fox, J.W.; Serrano, S.M. Timeline of key events in snake venom metalloproteinase research. J. Proteom. 2009, 72, 200-209. [CrossRef] [PubMed]
35. Markland, F.S.; Swenson, S. Snake venom metalloproteinases. Toxicon 2013, 62, 3-18. [CrossRef] [PubMed]
36. Baramova, E.N.; Shannon, J.D.; Bjarnason, J.B.; Gonias, S.L.; Fox, J.W. Interaction of hemorrhagic metalloproteinases with human alpha 2-macroglobulin. Biochemistry 1990, 29, 1069-1074. [CrossRef] [PubMed]
37. Gutierrez, J.M.; Rucavado, A.; Escalante, T.; Diaz, C. Hemorrhage induced by snake venom metalloproteinases:Biochemical and biophysical mechanisms involved in microvessel damage. Toxicon 2005, 45, 997-1011. [CrossRef] [PubMed]
38. Escalante, T.; Rucavado, A.; Fox, J.W.; Gutiérrez, J.M. Key events in microvascular damage induced by snake venom hemorrhagic metalloproteinases. J. Proteom. 2011, 74, 1781-1794. [CrossRef] [PubMed]
39. Bjarnason, J.B.; Fox, J.W. Hemorrhagic metalloproteinases from snake venoms. Pharmacol. Ther. 1994, 62, 325-372. [CrossRef]
40. Gomis-Ruth, F.X. Structural aspects of the metzincin clan of metalloendopeptidases. Mol. Biotechnol. 2003, 24, 157-202. [CrossRef]
41. Bjarnason, J.B.; Fox, J.W. Snake venom metalloendopeptidases: Reprolysins. Methods Enzym. 1995, 248, 345-368.
42. Gomis-Ruth, F.X.; Kress, L.F.; Bode,W. First structure of a snake venom metalloproteinase: A prototype for matrix metalloproteinases/collagenases. EMBO J. 1993, 12, 4151-4157. [PubMed]
43. Wolfsberg, T.G.; Straight, P.D.; Gerena, R.L.; Huovila, A.P.; Primakoff, P.; Myles, D.G.; White, J.M. ADAM, a widely distributed and developmentally regulated gene family encoding membrane proteins with a disintegrin and metalloprotease domain. Dev. Biol. 1995, 169, 378-383. [CrossRef] [PubMed]
44. Takeda, S. Three-dimensional domain architecture of the ADAM family proteinases. Semin. Cell. Dev. Biol. 2009, 20, 146-152. [CrossRef] [PubMed]
45. Takeda, S. VAP1: Snake venom homolog of mammalian ADAMs. In Handbook of Metalloproteins; Messerschmidt, A., Ed.; JohnWiley & Sons Inc.: Chichester, UK, 2010; Volume 5, pp. 699-713.
46. Takeda, S.; Takeya, H.; Iwanaga, S. Snake venom metalloproteinases: Structure, function and relevance to the mammalian ADAM/ADAMTS family proteins. Biochim. Biophys. Acta 2012, 1824, 164-176. [CrossRef] [PubMed]
47. Takeda, S. Structure-Function Relationship ofModular Domains of P-III Class Snake VenomMetalloproteinases. In Springer Reference (Toxinology); Gopalakrishnakone, P., Calvete, J.J., Eds.; Springer Science Business & Media:Dordrecht, The Netherlands, 2014; pp. 1-22.
48. Janes, P.W.; Saha, N.; Barton, W.A.; Kolev, M.V.; Wimmer-Kleikamp, S.H.; Nievergall, E.; Blobel, C.P.; Himanen, J.P.; Lackmann, M.; Nikolov, D.B. Adam meets Eph: An ADAM substrate recognition module acts as a molecular switch for ephrin cleavagein trans. Cell 2005, 123, 291-304. [CrossRef] [PubMed]
49. Wewer, U.M.; Morgelin, M.; Holck, P.; Jacobsen, J.; Lydolph, M.C.; Johnsen, A.H.; Kveiborg, M.; Albrechtsen, R. ADAM12 is a four-leafed clover: The excised prodomain remains bound to the mature enzyme. J. Biol. Chem. 2006, 281, 9418-9422. [CrossRef] [PubMed]
50. Mazzocca, A.; Coppari, R.; De Franco, R.; Cho, J.Y.; Libermann, T.A.; Pinzani, M.; Toker, A. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res. 2005, 65, 4728-4738. [CrossRef] [PubMed]
51. Roberts, C.M.; Tani, P.H.; Bridges, L.C.; Laszik, Z.; Bowditch, R.D. MDC-L, a novel metalloprotease disintegrin cysteine-rich protein family member expressed by human lymphocytes. J. Biol. Chem. 1999, 274, 29251-29259. [CrossRef] [PubMed]
52. Mueller, C.G.; Rissoan, M.C.; Salinas, B.; Ait-Yahia, S.; Ravel, O.; Bridon, J.M.; Briere, F.; Lebecque, S.; Liu, Y.J. Polymerase chain reaction selects a novel disintegrin proteinase from CD40-activated germinal center dendritic cells. J. Exp. Med. 1997, 186, 655-663. [CrossRef] [PubMed]
53. Akiyama, M.; Takeda, S.; Kokame, K.; Takagi, J.; Miyata, T. Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor. Proc. Natl. Acad. Sci. USA 2009, 106, 19274-19279. [CrossRef] [PubMed]
54. Le G, C.; Morice-Picard, F.; Dagoneau, N.; Wang, L.W.; Perrot, C.; Crow, Y.J.; Bauer, F.; Flori, E.; Prost-Squarcioni, C.; Krakow, D.; et al. ADAMTSL2 mutations in geleophysic dysplasia demonstrate a role for ADAMTS-like proteins in TGF-beta bioavailability regulation. Nat. Genet. 2008, 40, 1119-1123.
55. Ahram, D.; Sato, T.S.; Kohilan, A.; Tayeh, M.; Chen, S.; Leal, S.; Al-Salem, M.; El-Shanti, H. A homozygous mutation in ADAMTSL4 causes autosomal-recessive isolated ectopia lentis. Am. J. Hum. Genet. 2008, 84, 274-278. [CrossRef] [PubMed]
56. Fox, J.W.; Serrano, S.M. Insights into and speculations about snake venom metalloproteinase (SVMP) synthesis, folding and disulfide bond formation and their contribution to venom complexity. FEBS J. 2008, 275, 3016-3030. [CrossRef] [PubMed]
57. Clemetson, K.J. Snaclecs (snake C-type lectins) that inhibit or activate platelets by binding to receptors. Toxicon 2010, 56, 1236-1246. [CrossRef] [PubMed]
58. Casewell, N.R.; Wagstaff, S.C.; Harrison, R.A.; Renjifo, C.; Wüster, W. Domain loss facilitates accelerated evolution and neofunctionalization of duplicate snake venom metalloproteinase toxin genes. Mol. Biol. Evol. 2011, 28, 2637-2649. [CrossRef] [PubMed]
59. Moura-da-Silva, A.M.; Theakston, R.D.G.; Crampton, J.M. Evolution of disintegrin cysteine-rich and mammalian matrix-degrading metalloproteinases: Gene duplication and divergence of a common ancestor rather than convergent evolution. J. Mol. Evol. 1996, 43, 263-269. [CrossRef] [PubMed]
60. Juarez, P.; Comas, I.; Gonzalez-Candelas, F.; Calvete, J.J. Evolution of snake venom disintegrins by positive darwinian selection. Mol. Biol. Evol. 2008, 25, 2391-2407. [CrossRef] [PubMed]
61. Grams, F.; Huber, R.; Kress, L.F.; Moroder, L.; Bode,W. Activation of snake venom metalloproteinases by a cysteine switch-like mechanism. FEBS Lett. 1993, 335, 76-80. [CrossRef]
62. Wong, E.; Maretzky, T.; Peleg, Y.; Blobel, C.; Sagi, I. The Functional Maturation of A Disintegrin and Metalloproteinase (ADAM) 9, 10 and 17 Requires Processing at a Newly Identified Proprotein Convertase (PC) Cleavage Site. J. Biol. Chem. 2015, 290, 1-21. [CrossRef] [PubMed]
63. Majerus, E.M.; Zheng, X.; Tuley, E.A.; Sadler, J.E. Cleavage of the ADAMTS13 propeptide is not required for protease activity. J. Biol. Chem. 2003, 278, 46643-46648. [CrossRef] [PubMed]
64. Maskos, K.; Fernandez-Catalan, C.; Huber, R.; Bourenkov, G.P.; Bartunik, H.; Ellestad, G.A.; Reddy, P.; Wolfson, M.F.; Rauch, C.T.; Castner, B.J.; et al. Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme. Proc. Natl. Acad. Sci. USA 1998, 95, 3408-3412. [CrossRef] [PubMed]
65. Liu, H.; Shim, A.H.; He, X. Structural characterization of the ectodomain of a disintegrin and metalloproteinase-22 (ADAM22), a neural adhesion receptor instead of metalloproteinase: Insights on ADAM function. J. Biol. Chem. 2009, 284, 29077-29086. [CrossRef] [PubMed]
66. Gerhardt, S.; Hassall, G.; Hawtin, P.; McCall, E.; Flavell, L.; Minshull, C.; Hargreaves, D.; Ting, A.; Pauptit, R.A.; Parker, A.E.; et al. Crystal structures of human ADAMTS-1 reveal a conserved catalytic domain and a disintegrin-like domain with a fold homologous to cysteine-rich domains. J. Mol. Biol. 2007, 373, 891-902. [CrossRef] [PubMed]
67. Tallant, C.; Marrero, A.; Gomis-Rüth, F.X. Matrix metalloproteinases: Fold and function of their catalytic domains. Biochim. Biophys. Acta Mol. Cell Res. 2010, 1803, 20-28. [CrossRef] [PubMed]
68. Hall, T.; Shieh, H.S.; Day, J.E.; Caspers, N.; Chrencik, J.E.;Williams, J.M.; Pegg, L.E.; Pauley, A.M.; Moon, A.F.; Krahn, J.M.; et al. Structure of human ADAM-8 catalytic domain complexed with batimastat. Acta Crystallogr. Sect. F 2012, 68, 616-621. [CrossRef] [PubMed]
69. Düsterhöft, S.; Jung, S.; Hung, C.W.; Tholey, A.; Sönnichsen, F.D.; Grötzinger, J.; Lorenzen, I. Membrane-proximal domain of a disintegrin and metalloprotease-17 represents the putative molecular switch of its shedding activity operated by protein-disulfide isomerase. J. Am. Chem. Soc. 2013, 135, 5776-5781. [CrossRef] [PubMed]
70. Orth, P.; Reichert, P.; Wang, W.; Prosise, W.W.; Yarosh-Tomaine, T.; Hammond, G.; Ingram, R.N.; Xiao, L.; Mirza, U.A.; Zou, J.; et al. Crystal structure of the catalytic domain of human ADAM33. J. Mol. Biol. 2004, 335, 129-137. [CrossRef] [PubMed]
71. Mosyak, L.; Georgiadis, K.; Shane, T.; Svenson, K.; Hebert, T.; McDonagh, T.; Mackie, S.; Olland, S.; Lin, L.; Zhong, X.; et al. Crystal structures of the two major aggrecan degrading enzymes, ADAMTS4 and ADAMTS5. Protein Sci. 2008, 17, 16-21. [CrossRef] [PubMed]
72. Shieh, H.S.; Mathis, K.J.; Williams, J.M.; Hills, R.L.; Wiese, J.F.; Benson, T.E.; Kiefer, J.R.; Marino, M.H.; Carroll, J.N.; Leone, J.W.; et al. A. High resolution crystal structure of the catalytic domain of ADAMTS-5 (aggrecanase-2). J. Biol. Chem. 2008, 283, 1501-1507. [CrossRef] [PubMed]
73. Akiyama, M.; Nakayama, D.; Takeda, S.; Kokame, K.; Takagi, J.; Miyata, T. Crystal structure and enzymatic activity of an ADAMTS-13 mutant with the East Asian-specific P475S polymorphism. J. Thromb. Haemost. 2013, 11, 1399-1406. [CrossRef] [PubMed]
74. Gong, W.; Zhu, X.; Liu, S.; Teng, M.; Niu, L. Crystal structures of acutolysin A, a three-disulfide hemorrhagic zinc metalloproteinase from the snake venom of Agkistrodon acutus. J. Mol. Biol. 1998, 283, 657-668. [CrossRef] [PubMed]
75. Zhu, X.Y.; Teng, M.K.; Niu, L.W. Structure of acutolysin-C, a haemorrhagic toxin from the venom of Agkistrodon acutus, providing further evidence for the mechanism of the pH-dependent proteolytic reaction of zinc metalloproteinases. Acta Crystallogr. Sect. D 1999, 55, 1834-1841. [CrossRef]
76. Gomis-Rüth, F.X.; Kress, L.F.; Kellermann, J.; Mayr, I.; Lee, X.; Huber, R.; Bode, W. Refined 2.0 A X-ray crystal structure of the snake venom zinc-endopeptidase adamalysin II. Primary and tertiary structure determination, refinement, molecular structure and comparison with astacin, collagenase and thermolysin. J. Mol. Biol. 1994, 239, 513-544. [CrossRef] [PubMed]
77. Zhang, D.; Botos, I.; Gomis-Ruth, F.X.; Doll, R.; Blood, C.; Njoroge, F.G.; Fox, J.W.; Bode, W.; Meyer, E.F. Structural interaction of natural and synthetic inhibitors with the venom metalloproteinase, atrolysin C (form d). Proc. Natl. Acad. Sci. USA 1994, 91, 8447-8451. [CrossRef] [PubMed]
78. Watanabe, L.; Shannon, J.D.; Valente, R.H.; Rucavado, A.; Alape-Giron, A.; Kamiguti, A.S.; Theakston, R.D.; Fox, J.W.; Gutierrez, J.M.; Arni, R.K. Amino acid sequence and crystal structure of BaP1, a metalloproteinase from Bothrops asper snake venom that exerts multiple tissue-damaging activities. Protein Sci. 2003, 12, 2273-2281. [CrossRef] [PubMed]
79. Akao, P.K.; Tonoli, C.C.C.; Navarro, M.S.; Cintra, A.C.O.; Neto, J.R.; Arni, R.K.; Murakami, M.T. Structural studies of BmooMPalpha-I, a non-hemorrhagic metalloproteinase from Bothrops moojeni venom. Toxicon 2010, 55, 361-368. [CrossRef] [PubMed]
80. Lou, Z.; Hou, J.; Liang, X.; Chen, J.; Qiu, P.; Liu, Y.; Li, M.; Rao, Z.; Yan, G. Crystal structure of a non-hemorrhagic fibrin(ogen)olytic metalloproteinase complexed with a novel natural tri-peptide inhibitor from venom of Agkistrodon acutus. J. Struct. Biol. 2005, 152, 195-203. [CrossRef] [PubMed]
81. Kumasaka, T.; Yamamoto, M.; Moriyama, H.; Tanaka, N.; Sato, M.; Katsube, Y.; Yamakawa, Y.; Omori-Satoh, T.; Iwanaga, S.; Ueki, T. Crystal structure of H2-proteinase from the venom of Trimeresurus flavoviridis. J. Biochem. 1996, 119, 49-57. [CrossRef] [PubMed]
82. Chou, T.L.;Wu, C.H.; Huang, K.F.;Wang, A.H.J. Crystal structure of a Trimeresurus mucrosquamatus venom metalloproteinase providing new insights into the inhibition by endogenous tripeptide inhibitors. Toxicon 2013, 71, 140-146. [CrossRef] [PubMed]
83. Huang, K.F.; Chiou, S.H.; Ko, T.P.; Yuann, J.M.; Wang, A.H. The 1.35 A structure of cadmium-substituted TM-3, a snake-venom metalloproteinase from Taiwan habu: Elucidation of a TNFalpha-converting enzyme-like active-site structure with a distorted octahedral geometry of cadmium. Acta Crystallogr. D 2002, 58, 1118-1128. [CrossRef] [PubMed]
84. Zhu, Z.; Gao, Y.; Yu, Y.; Zhang, X.; Zang, J.; Teng, M.; Niu, L. Structural basis of the autolysis of AaHIV suggests a novel target recognizing model for ADAM/reprolysin family proteins. Biochem. Biophys. Res. Commun. 2009, 386, 159-164. [CrossRef] [PubMed]
85. Guan, H.H.; Goh, K.S.; Davamani, F.;Wu, P.L.; Huang, Y.W.; Jeyakanthan, J.;Wu,W.G.; Chen, C.J. Structures of two elapid snake venom metalloproteases with distinct activities highlight the disulfide patterns in the D domain of ADAMalysin family proteins. J. Struct. Biol. 2009, 169, 294-303. [CrossRef] [PubMed]
86. Muniz, J.R.; Ambrosio, A.L.; Selistre-de-Araujo, H.S.; Cominetti, M.R.; Moura-da-Silva, A.M.; Oliva, G.; Garratt, R.C.; Souza, D.H. The three-dimensional structure of bothropasin, the main hemorrhagic factor from Bothrops jararaca venom: Insights for a new classification of snake venom metalloprotease subgroups. Toxicon 2008, 52, 807-816. [CrossRef] [PubMed]
87. Igarashi, T.; Araki, S.; Mori, H.; Takeda, S. Crystal structures of catrocollastatin/VAP2B reveal a dynamic, modular architecture of ADAM/adamalysin/reprolysin family proteins. FEBS Lett. 2007, 581, 2416-2422. [CrossRef] [PubMed]
88. Takeda, S.; Igarashi, T.; Mori, H. Crystal structure of RVV-X: An example of evolutionary gain of specificity by ADAM proteinases. FEBS Lett. 2007, 581, 5859-5864. [CrossRef] [PubMed]
89. Gomis-Ruth, F.X.; Botelho, T.O.; Bode,W. A standard orientation for metallopeptidases. Biochim. Biophys. Acta 2012, 1824, 157-163. [CrossRef] [PubMed]
90. Gomis-Ruth, F.X. Catalytic domain architecture of metzincin metalloproteases. J. Biol. Chem. 2009, 284, 15353-15357. [CrossRef] [PubMed]
91. Takeya, H.; Nishida, S.; Nishino, N.; Makinose, Y.; Omori-Satoh, T.; Nikai, T.; Sugihara, H.; Iwanaga, S. Primary structures of platelet aggregation inhibitors (disintegrins) autoproteolytically released from snake venom hemorrhagic metalloproteinases and new fluorogenic peptide substrates for these enzymes. J. Biochem. 1993, 113, 473-483. [PubMed]
92. Gardner, M.D.; Chion, C.K.; De Groot, R.; Shah, A.; Crawley, J.T.; Lane, D.A. A functional calcium-binding site in the metalloprotease domain of ADAMTS13. Blood 2009, 113, 1149-1157. [CrossRef] [PubMed]
93. Igarashi, T.; Oishi, Y.; Araki, S.; Mori, H.; Takeda, S. Crystallization and preliminary X-ray crystallographic analysis of two vascular apoptosis-inducing proteins (VAPs) from Crotalus atrox venom. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2006, 62, 688-691. [CrossRef] [PubMed]
94. Shimokawa, K.; Shannon, J.D.; Jia, L.G.; Fox, J.W. Sequence and biological activity of catrocollastatin-C:A disintegrin-like/cysteine-rich two-domain protein from Crotalus atrox venom. Arch. Biochem. Biophys. 1997, 343, 35-43. [CrossRef] [PubMed]
95. Usami, Y.; Fujimura, Y.; Miura, S.; Shima, H.; Yoshida, E.; Yoshioka, A.; Hirano, K.; Suzuki, M.; Titani, K. A 28 kDa-protein with disintegrin-like structure (jararhagin-C) purified from Bothrops jararaca venom inhibits collagen- and ADP-induced platelet aggregation. Biochem. Biophys. Res. Commun. 1994, 201, 331-339. [CrossRef] [PubMed]
96. Blobel, C.P.; Myles, D.G.; Primakoff, P.; White, J.M. Proteolytic processing of a protein involved in sperm-egg fusion correlates with acquisition of fertilization competence. J. Cell Biol. 1990, 111, 69-78. [CrossRef] [PubMed]
97. Fujii, Y.; Okuda, D.; Fujimoto, Z.; Horii, K.; Morita, T.; Mizuno, H. Crystal structure of trimestatin, a disintegrin containing a cell adhesion recognition motif RGD. J. Mol. Biol. 2003, 332, 1115-1122. [CrossRef]
98. Kini, R.M.; Evans, H.J. Structural domains in venom proteins: Evidence that metalloproteinases and nonenzymatic platelet aggregation inhibitors (disintegrins) from snake venoms are derived by proteolysis from a common precursor. Toxicon 1992, 30, 265-293. [CrossRef]
99. Calvete, J.J.; Marcinkiewicz, C.; Monleon, D.; Esteve, V.; Celda, B.; Juarez, P.; Sanz, L. Snake venom disintegrins: Evolution of structure and function. Toxicon 2005, 45, 1063-1074. [CrossRef] [PubMed]
100. Calvete, J.J. The continuing saga of snake venom disintegrins. Toxicon 2013, 62, 40-49. [CrossRef] [PubMed]
101. Okuda, D.; Koike, H.; Morita, T. A new gene structure of the disintegrin family: A subunit of dimeric disintegrin has a short coding region. Biochemistry 2002, 41, 14248-14254. [CrossRef] [PubMed]
102. Moura-da-Silva, A.M.; Della-Casa, M.S.; David, A.S.; Assakura, M.T.; Butera, D.; Lebrun, I.; Shannon, J.D.; Serrano, S.M.; Fox, J.W. Evidence for heterogeneous forms of the snake venom metalloproteinase jararhagin:A factor contributing to snake venom variability. Arch. Biochem. Biophys. 2003, 409, 395-401. [CrossRef]
103. Carbajo, R.J.; Sanz, L.; Perez, A.; Calvete, J.J. NMR structure of bitistatin-A missing piece in the evolutionary pathway of snake venom disintegrins. FEBS J. 2015, 282, 341-360. [CrossRef] [PubMed]
104. Willems, S.H.; Tape, C.J.; Stanley, P.L.; Taylor, N.A.; Mills, I.G.; Neal, D.E.; McCafferty, J.; Murphy, G. Thiol isomerases negatively regulate the cellular shedding activity of ADAM17. Biochem. J. 2010, 428, 439-450. [CrossRef] [PubMed]
105. Smith, K.M.; Gaultier, A.; Cousin, H.; Alfandari, D.; White, J.M.; DeSimone, D.W. The cysteine-rich domain regulates ADAM protease function in vivo. J. Cell Biol. 2002, 159, 893-902. [CrossRef] [PubMed]
106. Reddy, P.; Slack, J.L.; Davis, R.; Cerretti, D.P.; Kozlosky, C.J.; Blanton, R.A.; Shows, D.; Peschon, J.J.; Black, R.A. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J. Biol. Chem. 2000, 275, 14608-14614. [CrossRef] [PubMed]
107. Gaultier, A.; Cousin, H.; Darribere, T.; Alfandari, D.; Darribe, T. ADAM13 disintegrin and cysteine-rich domains bind to the second heparin-binding domain of fibronectin. J. Biol. Chem. 2002, 277, 23336-23344. [CrossRef] [PubMed]
108. Iba, K.; Albrechtsen, R.; Gilpin, B.; Frohlich, C.; Loechel, F.; Zolkiewska, A.; Ishiguro, K.; Kojima, T.; Liu, W.; Langford, J.K.; et al. The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to beta1 integrin-dependent cell spreading. J. Cell. Biol. 2000, 149, 1143-1156. [CrossRef] [PubMed]
109. Lorenzen, I.; Lokau, J.; Dusterhoft, S.; Trad, A.; Garbers, C.; Scheller, J.; Rose-John, S.; Grotzinger, J. The membrane-proximal domain of A Disintegrin and Metalloprotease 17 (ADAM17) is responsible for recognition of the interleukin-6 receptor and interleukin-1 receptor II. FEBS Lett. 2012, 586, 1093-1100. [CrossRef] [PubMed]
110. Düsterhöft, S.; Höbel, K.; Oldefest, M.; Lokau, J.; Waetzig, G.H.; Chalaris, A.; Garbers, C.; Scheller, J.; Rose-John, S.; Lorenzen, I.; et al. A disintegrin and metalloprotease 17 dynamic interaction sequence, the sweet tooth for the human interleukin 6 receptor. J. Biol. Chem. 2014, 289, 16336-16348. [CrossRef] [PubMed]
111. Düsterhöft, S.; Michalek, M.; Kordowski, F.; Oldefest, M.; Sommer, A.; Röseler, J.; Reiss, K.; Grötzinger, J.; Lorenzen, I. Extracellular Juxtamembrane Segment of ADAM17 Interacts with Membranes and is Essential for Its Shedding Activity. Biochemistry 2015, 54, 5791-5801. [CrossRef] [PubMed]
112. Doley, R.; Kini, R.M. Protein complexes in snake venom. Cell Mol. Life Sci. 2009, 66, 2851-2871. [CrossRef] [PubMed]
113. Kosasih, H.J.; Last, K.; Rogerson, F.M.; Golub, S.B.; Gauci, S.J.; Russo, V.C.; Stanton, H.; Wilson, R.; Lamande, S.R.; Holden, P.; et al. A Disintegrin and Metalloproteinase with Thrombospondin Motifs-5 (ADAMTS-5) Forms Catalytically Active Oligomers. J. Biol. Chem. 2016, 291, 3197-3208. [CrossRef] [PubMed]
114. Hojima, Y.; Mckenzie, J.; van der Rest, M.; Prockop, D.J. Type I Procollagen N-proteinase from Chick Embryo Tendons. Enzyme 1989, 264, 11336-11345.
115. Furlan, M.; Robles, R.; Lamie, B. Partial purification and characterization of a protease from human plasma cleaving vonWillebrand factor to fragments produced by in vivo proteolysis. Blood 1996, 87, 4223-4234. [PubMed]
116. Lorenzen, I.; Trad, A.; Grötzinger, J. Multimerisation of A disintegrin and metalloprotease protein-17 (ADAM17) is mediated by its EGF-like domain. Biochem. Biophys. Res. Commun. 2011, 415, 330-336. [CrossRef] [PubMed]
117. Masuda, S.; Araki, S.; Yamamoto, T.; Kaji, K.; Hayashi, H. Purification of a vascular apoptosis-inducing factor from hemorrhagic snake venom. Biochem. Biophys. Res. Commun. 1997, 235, 59-63. [CrossRef] [PubMed]
118. Nikai, T.; Taniguchi, K.; Komori, Y.; Masuda, K.; Fox, J.W.; Sugihara, H. Primary structure and functional characterization of bilitoxin-1, a novel dimeric P-II snake venom metalloproteinase from Agkistrodon bilineatus venom. Arch. Biochem. Biophys. 2000, 378, 6-15. [CrossRef] [PubMed]
119. Schiffman, S.; Theodor, I.; Rapaport, S.I. Separation from Russell’s viper venom of one fraction reacting with factor X and another reacting with factor V. Biochemistry 1969, 8, 1397-1405. [CrossRef] [PubMed]
120. Morita, T. Proteases which activate factor X. In Enzymes from Snake Venom; Bailey, G.S., Ed.; InterScience Publishers: Alaken, CO, USA, 1998; pp. 179-208.
121. Siigur, J.; Siigur, E. Activation of factor X by snake venom proteases. In Toxins and Hemostasis: From Bench to Bedside; Kini, R., Clemetson, K.J., Markland, F.S., McLane, M.A., Morita, T., Eds.; Springer Science & Business Media:Dordrecht, The Netherlands, 2010; pp. 447-464.
122. Siigur, E.; Tonismagi, K.; Trummal, K.; Samel, M.; Vija, H.; Subbi, J.; Siigur, J. Factor X activator from Vipera lebetina snake venom, molecular characterization and substrate specificity. Biochim. Biophys. Acta 2001, 1568, 90-98. [CrossRef]
123. Hjort, P.F. Intermediate reactions in the coagulation of blood with tissue thromboplastin; convertin, accelerin, prothrombinase. Scand. J. Clin. Lab. Investig. 1957, 9, 1-183. [PubMed]
124. Tokunaga, F.; Nagasawa, K.; Tamura, S.; Miyata, T.; Iwanaga, S.; Kisiel,W. The factor V-activating enzyme (RVV-V) from Russell’s viper venom. Identification of isoproteins RVV-V alpha, -V beta, and -V gamma and their complete amino acid sequences. J. Biol. Chem. 1988, 263, 17471-17481. [PubMed]
125. Takeya, H.; Nishida, S.; Miyata, T.; Kawada, S.; Saisaka, Y.; Morita, T.; Iwanaga, S. Coagulation factor X activating enzyme from Russell’s viper venom (RVV-X). A novel metalloproteinase with disintegrin (platelet aggregation inhibitor)-like and C-type lectin-like domains. J. Biol. Chem. 1992, 267, 14109-14117. [PubMed]
126. Mizuno, H.; Fujimoto, Z.; Koizumi, M.; Kano, H.; Atoda, H.; Morita, T. Structure of coagulation factors IX/X-binding protein, a heterodimer of C-type lectin domains. Nat. Struct. Biol. 1997, 4, 438-441. [CrossRef] [PubMed]
127. Takeda, S. Structural aspects of the factor X activator RVV-X from Russell’s viper venom. In Toxins and Hemostasis: From Bench to Bedside; Kini, R., Clemetson, K.J., Markland, F.S., McLane, M.A., Morita, T., Eds.; Springer Science Business & Media: Dordrecht, The Netherlands, 2010; pp. 465-484.
128. Mizuno, H.; Fujimoto, Z.; Atoda, H.; Morita, T. Crystal structure of an anticoagulant protein in complex with the Gla domain of factor X. Proc. Natl. Acad. Sci. USA 2001, 98, 7230-7234. [CrossRef] [PubMed]
129. Nakayama, D.; Ben Ammar, Y.; Miyata, T.; Takeda, S. Structural basis of coagulation factor V recognition for cleavage by RVV-V. FEBS Lett. 2011, 585, 3020-3025. [CrossRef] [PubMed]
130. Yamada, D.; Sekiya, F.; Morita, T. Isolation and characterization of carinactivase, a novel prothrombin activator in Echis carinatus venom with a unique catalytic mechanism. J. Biol. Chem. 1996, 271, 5200-5207. [PubMed]
131. Yamada, D.; Morita, T. Purification and characterization of a Ca2+-dependent prothrombin activator, multactivase, from the venom of Echis multisquamatus. J. Biochem. 1997, 122, 991-997. [CrossRef] [PubMed]
132. Kokame, K.; Nobe, Y.; Kokubo, Y.; Okayama, A.; Miyata, T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br. J. Haematol. 2005, 129, 93-100. [CrossRef] [PubMed]
133. Tan, K.; Duquette, M.; Liu, J.H.; Dong, Y.; Zhang, R.; Joachimiak, A.; Lawler, J.; Wang, J.H. Crystal structure of the TSP-1 type 1 repeats: A novel layered fold and its biological implication. J. Cell Biol. 2002, 159, 373-382. [CrossRef] [PubMed]
134. Akiyama, M.; Takeda, S.; Kokame, K.; Takagi, J.; Miyata, T. Production, crystallization and preliminary crystallographic analysis of an exosite-containing fragment of human von Willebrand factor-cleaving proteinase ADAMTS13. Acta Crystallogr. Sect. F 2009, 65, 739-742. [CrossRef] [PubMed]
135. Zander, C.B.; Cao,W.; Zheng, X.L. ADAMTS13 and vonWillebrand factor interaction. Curr. Opin. Hematol. 2015, 22, 452-459. [CrossRef] [PubMed]
136. Crawley, J.T.B.; De Groot, R.; Xiang, Y.; Luken, B.M.; Lane, D.A. Untravelling the scissile bond: How ADAMTS13 recognises and cleaves von Willebrand factor. Blood 2011, 118, 3212-3221. [CrossRef] [PubMed]
137. Sadler, J.E. Biochemistry and genetics of von Willebrand factor. Annu. Rev. Biochem. 1998, 67, 395-424. [CrossRef] [PubMed]
138. Ruggeri, Z.M. Von Willebrand factor, platelets and endothelial cell interactions. J. Thromb. Haemost. 2003, 1, 1335-1342. [CrossRef] [PubMed]
139. Springer, T. a. Biology and physics of von Willebrand factor concatamers. J. Thromb. Haemost. 2011. [CrossRef] [PubMed]
140. Moake, J.L.; Rudy, C.K.; Troll, J.H.; Weinstein, M.J.; Colannino, N.M.; Azocar, J.; Seder, R.H.; Hong, S.L.; Deykin, D. Unusually large plasma factor VIII: Von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N. Engl. J. Med. 1982, 307, 1432-1435. [CrossRef] [PubMed]
141. Furlan, M.; Robles, R.; Galbusera, M.; Remuzzi, G.; Kyrle, P.A.; Brenner, B.; Krause, M.; Scharrer, I.; Aumann, V.; Mittler, U.; et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N. Engl. J. Med. 1998, 339, 1578-1584. [CrossRef] [PubMed]
142. Dent, J.A.; Berkowitz, S.D.; Ware, J.; Kasper, C.K.; Ruggeri, Z.M. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA vonWillebrand factor. Proc. Natl. Acad. Sci. USA 1990, 87, 6306-6310. [CrossRef] [PubMed]
143. Tsai, H.M.; Sussman, I.I.; Nagel, R.L. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 1994, 83, 2171-2179. [PubMed]
144. Zhang, X.; Halvorsen, K.; Zhang, C.Z.; Wong, W.P.; Springer, T.A. Mechanoenzymatic cleavage of the ultralarge vascular protein vonWillebrand factor. Science 2009, 324, 1330-1334. [CrossRef] [PubMed]
145. Soejima, K.; Matsumoto, M.; Kokame, K.; Yagi, H.; Ishizashi, H.; Maeda, H.; Nozaki, C.; Miyata, T.; Fujimura, Y.; Nakagaki, T. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood 2003, 102, 3232-3237. [CrossRef] [PubMed]
146. Zheng, X.; Nishio, K.; Majerus, E.M.; Sadler, J.E. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J. Biol. Chem. 2003, 278, 30136-30141. [CrossRef] [PubMed]
147. Ai, J.; Smith, P.;Wang, S.; Zhang, P.; Zheng, X.L. The Proximal Carboxyl-terminal Domains of ADAMTS13 Determine Substrate Specificity and Are All Required for Cleavage of vonWillebrand Factor. J. Biol. Chem. 2005, 280, 29428-29434. [CrossRef] [PubMed]
148. Gao,W.; Anderson, P.J.; Sadler, J.E. Extensive contacts between ADAMTS13 exosites and vonWillebrand factor domain A2 contribute to substrate specificity. Blood 2008, 112, 1713-1719. [CrossRef] [PubMed]
149. Kokame, K.; Matsumoto, M.; Fujimura, Y.; Miyata, T. VWF73, a region from D1596 to R1668 of vonWillebrand factor, provides a minimal substrate for ADAMTS-13. Blood 2004, 103, 607-612. [CrossRef] [PubMed]
150. De Groot, R.; Bardhan, A.; Ramroop, N.; Lane, D.A.; Crawley, J.T.B. Essential role of the disintegrin-like domain in ADAMTS13 function. Blood 2009, 113, 5609-5616. [CrossRef] [PubMed]
151. Xiang, Y.; De Groot, R.; Crawley, J.T.B.; Lane, D.A. Mechanism of vonWillebrand factor scissile bond cleavage by a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). Proc. Natl. Acad. Sci. USA 2011, 108, 11602-11607. [CrossRef] [PubMed]
152. De Groot, R.; Lane, D.A.; Crawley, J.T.B. The role of the ADAMTS13 cysteine-rich domain in VWF binding and proteolysis. Blood 2015, 125, 1968-1975. [CrossRef] [PubMed]
153. Zhang, Q.; Zhou, Y.F.; Zhang, C.Z.; Zhang, X.; Lu, C.; Springer, T.A. Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein vonWillebrand factor. Proc. Natl. Acad. Sci. USA 2009, 106, 9226-9231. [CrossRef] [PubMed]
154. Kokame, K.; Matsumoto, M.; Soejima, K.; Yagi, H.; Ishizashi, H.; Funato, M.; Tamai, H.; Konno, M.; Kamide, K.; Kawano, Y.; et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for vonWillebrand factor-cleaving protease activity. Proc. Natl. Acad. Sci. USA 2002, 99, 11902-11907. [CrossRef] [PubMed]
155. Gao, W.; Anderson, P.J.; Majerus, E.M.; Tuley, E.A.; Sadler, J.E. Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease. Proc. Natl. Acad. Sci. USA 2006, 103, 19099-19104. [CrossRef] [PubMed]
156. Jin, S.; Skipwith, C.G.; Zheng, X.L.; Dc, W. Amino acid residues Arg 659, Arg 660, and Tyr 661 in the spacer domain of ADAMTS13 are critical for cleavage of vonWillebrand factor. Blood 2010, 115, 2300-2310. [CrossRef] [PubMed]
157. Pos, W.; Crawley, J.T. B.; Fijnheer, R.; Voorberg, J.; Lane, D.A.; Luken, B.M. An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood 2010, 115, 1640-1649. [CrossRef] [PubMed]
158. Jian, C.; Xiao, J.; Gong, L.; Skipwith, C.G.; Jin, S.Y.; Kwaan, H.C.; Zheng, X.L. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Blood 2012, 119, 3836-3843. [CrossRef] [PubMed]
159. Gendron, C.; Kashiwagi, M.; Lim, N.H.; Enghild, J.J.; Thøgersen, I.B.; Hughes, C.; Caterson, B.; Nagase, H. Proteolytic Activities of Human ADAMTS-5. J. Biol. Chem. 2007, 282, 18294-18306. [CrossRef] [PubMed]
160. Santamaria, S.; Yamamoto, K.; Botkjaer, K.; Tape, C.; Dyson, M.R.; McCafferty, J.; Murphy, G.; Nagase, H. Antibody-based exosite inhibitors of ADAMTS-5 (aggrecanase-2). Biochem. J. 2015, 471, 391-401. [CrossRef] [PubMed]
161. Nishi, E.; Hiraoka, Y.; Yoshida, K.; Okawa, K.; Kita, T. Nardilysin Enhances Ectodomain Shedding of Heparin-binding Epidermal Growth Factor-like Growth Factor through Activation of Tumor Necrosis Factor-alpha-converting Enzyme. J. Biol. Chem. 2006, 281, 31164-31172. [CrossRef] [PubMed]
162. Nakayama, H.; Fukuda, S.; Inoue, H.; Nishida-Fukuda, H.; Shirakata, Y.; Hashimoto, K.; Higashiyama, S. Cell surface annexins regulate ADAM-mediated ectodomain shedding of proamphiregulin. Mol. Biol. Cell. 2012, 23, 1964-1975. [CrossRef] [PubMed]
163. Maney, S.K.; McIlwain, D.R.; Polz, R.; Pandyra, A.A.; Sundaram, B.; Wolff, D.; Ohishi, K.; Maretzky, T.; Brooke, M.A.; Evers, A.; et al. Deletions in the cytoplasmic domain of iRhom1 and iRhom2 promote shedding of the TNF receptor by the protease ADAM17. Sci. Signal. 2015, 8, ra109. [CrossRef] [PubMed]
164. Muia, J.; Zhu, J.; Gupta, G.; Haberichter, S.L.; Friedman, K.D.; Feys, H.B.; Deforche, L.; Vanhoorelbeke, K.; Westfield, L.A.; Roth, R.; et al. Allosteric activation of ADAMTS13 by von Willebrand factor. Proc. Natl. Acad. Sci. USA 2014, 111, 18584-18589. [CrossRef] [PubMed]
165. South, K.; Luken, B.M.; Crawley, J.T.B.; Phillips, R.; Thomas, M.; Collins, R.F.; Deforche, L.; Vanhoorelbeke, K.; Lane, D.A. Conformational activation of ADAMTS13. Proc. Natl. Acad. Sci. USA 2014, 111, 18578-18583. [CrossRef] [PubMed]
166. Coussens, L.M. Matrix Metalloproteinase Inhibitors and Cancer: Trials and Tribulations. Siecnce 2009, 295, 2387-2393. [CrossRef] [PubMed]
167. Moss, M.L.; Bomar, M.; Liu, Q.; Sage, H.; Dempsey, P.; Lenhart, P.M.; Gillispie, P.A.; Stoeck, A.; Wildeboer, D.; Bartsch, J.W.; et al. The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events. J. Biol. Chem. 2007, 282, 35712-35721. [CrossRef] [PubMed]
168. Miller, M.A.; Moss, M.L.; Powell, G.; Petrovich, R.; Edwards, L.; Meyer, A.S.; Griffith, L.G.; Lauffenburger, D.A. Targeting autocrine HB-EGF signaling with specific ADAM12 inhibition using recombinant ADAM12 prodomain. Sci. Rep. 2015, 5. [CrossRef] [PubMed]
169. Tape, C.J.; Willems, S.H.; Dombernowsky, S.L.; Stanley, P.L.; Fogarasi, M.; Ouwehand, W.; McCafferty, J.; Murphy, G. Cross-domain inhibition of TACE ectodomain. Proc. Natl. Acad. Sci. USA 2011, 108, 5578-5583. [CrossRef] [PubMed]
170. Larkin, J.; Lohr, T.A.; Elefante, L.; Shearin, J.; Matico, R.; Su, J.; Xue, Y.; Liu, F.; Genell, C.; Miller, R.E.; et al. Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification. Osteoarthr. Cartil. 2015, 23, 1254-1266. [CrossRef] [PubMed]
171. Shiraishi, A.; Mochizuki, S.; Miyakoshi, A.; Kojoh, K.; Okada, Y. Development of human neutralizing antibody to ADAMTS4 (aggrecanase-1) and ADAMTS5 (aggrecanase-2). Biochem. Biophys. Res. Commun. 2015, 4, 1-8. [CrossRef] [PubMed]